Clinical trial · Interventional
TILA-TACE in Treatment of Hepatocellular Carcinoma
A Prospective Non-controlled Single-arm Study of TILA-TACE in Treatment of Hepatocellular Carcinoma
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
To validate the tumor response rate: in the previous study, the investigators showed that TILA-TACE achieved 100% tumor response rate. However, as the study sample size was 40, the investigators need to validate the tumor response rate using a larger sample size; To validate the overall survival: in the previous study, the investigators showed that TILA-TACE significantly prolonged the overall survival of the patients with large and massive tumor. Again, the sample size was small, the investigators need to validate the data using a large sample size.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Overall Survival | — | UNRESOLVED | — |
| Tumor Response Rate | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| TILA-TACE treatment | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- TILA-TACE group
- interventionNames
- Procedure: TILA-TACE treatment
Primary outcomes (1)
- measure
- The response to treatment
- timeFrame
- 1 month after therapy
- description
- Viable tumors were assessed by MRI according to EASL criteria. The enhanced and non-enhanced areas represent viable and necrotic tumors. At least 2 radiologists evaluate the approximate viable tumor residues (%) of total tumor volume (Total tumor volume was the sum of viable and necrotic volume). The response to treatment is defined by the Viable Tumor Residues (%) as below: complete response (CR), no obvious viable residuals; near complete response (NCR), viable residuals \<10%; partial response (PR), viable residuals \>10% but \< 50%; stable disease (SD), viable tumor residuals between \>50% but ≤100%; and progressive disease (PD), viable tumors \> 100%.
Secondary outcomes (1)
- measure
- Lifetime (months)
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria: * Hepatocellular carcinoma is confirmed by tissue pathology or in accordance with clinical diagnosis standard; * ECOG score 0-1; * HCC BCLC grading 0, A, B, C; * Child-Pugh score prior to therapy A and B; * As judged by investigators, the patient can comply with the study protocol; * Patient voluntarily participates in this study, understands the process of the study, and is willing to sign the written consent form. Exclusion Criteria: * HCC BCLC grading D; * Child-Pugh score prior to therapy C.
References
Publications (0)
Data not yet available